PharmiWeb Recruiter Blog

10 Time Management Tips for Recruiters

10 Time Management Tips for Recruiters

At work, less than 18% of people use a time management system, and 1 in 8 never feel in control of their work. With the Life Science industry demanding more from recruiters and hiring managers every day, now is the time to review how your time is currently being spent, and implement new techniques to help you stay productive and motivated at work.

Read more
Merck

Merck to Acquire Imago BioSciences, Inc.

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.

Read more
Salary Transparency and the Gender Pay Gap in the Pharmaceutical Industry

Salary Transparency and the Gender Pay Gap in the Pharmaceutical Industry

Research by Pharmaceutical Technology found that in the 2021-2022 reporting year, 95.7% of pharmaceutical companies with a headcount above 250 pay their male employees higher than their female employees. The same research found that across the pharmaceutical industry, median hourly pay was 10% higher for males than females, placing the industry below the UK average of 11.6%.

Read more
Velocity

Velocity Clinical Research expands to UK

London, U.K., 17 November 2022: Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces its expansion into the U.K. with the acquisition of multi-site company Egin Research.

Read more
Avanzanite Bioscience

Avanzanite Bioscience Launches Novel Business Model to Commercialize Innovative Medicines for Rare Diseases in Europe

  • Establishes first-in-class biopharmaceutical commercialization platform specifically addressing rare diseases in Europe
  • Secured exclusive rights in 26 European Countries to an investigational orphan medicine for the treatment of an ultra-rare ophthalmologic disease, currently under review by the European Medicines Agency for marketing approval
  • Founded by biopharmaceutical executives Adam Plich, CEO, and Anant Murthy, Board Advisor, with the backing of a seasoned Advisory Board

AMSTERDAM--(BUSINESS WIRE)--Today, Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”) officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with these biopharmaceutical collaborators through flexible, bespoke licensing and distribution partnerships across Europe. The Company’s novel business model enables the global commercialization of promising medicines and addresses the unsustainable inequities in access to innovative orphan drugs across Europe.

Read more